T. Rowe Price Investment Management, Inc. filed a Schedule 13G with the SEC on November 16, 2026, disclosing a beneficial ownership position in Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 10,017,904 shares of Alnylam Pharmaceuticals common stock.
  • Percent of class: The reported position represents 7.5% of the class of securities.
  • Sole voting power: The filing disclosed sole voting power over 9,530,952 shares.
  • Sole dispositive power: Sole power to dispose of or direct the disposition of all 10,017,904 shares was reported, with no shared dispositive power.
  • Triggering date: The date of event requiring the filing was stated as September 30, 2026.
  • Filer classification: T. Rowe Price Investment Management, Inc. is identified as an investment adviser (type "IA"), organized in Maryland, with offices at 1307 Point Street, Baltimore, MD 21231.

T. Rowe Price Investment Management Discloses 10,017,904-Share Position in Alnylam

According to the Schedule 13G filing, T. Rowe Price Investment Management, Inc. reported aggregate beneficial ownership of 10,017,904 shares of Alnylam Pharmaceuticals Inc. common stock (CUSIP 02043Q107), representing 7.5% of the outstanding class as of September 30, 2026. The filing was signed by Ellen York, Vice President, on November 16, 2026.

The filing disclosed that T. Rowe Price Investment Management holds sole voting power over 9,530,952 shares and sole dispositive power over the full 10,017,904 shares. Shared voting power and shared dispositive power were each reported as zero. The company certified, as required under Schedule 13G, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

The filing also includes a declaration that "the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied." Alnylam Pharmaceuticals is headquartered at 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142, according to the filing. Items 5 through 9 of the Schedule 13G, covering ownership of 5% or less, ownership on behalf of another person, subsidiary identification, group membership, and dissolution of group, were each marked "Not Applicable."

What Was Disclosed

T. Rowe Price Investment Management, Inc. filed a Schedule 13G reporting beneficial ownership of 10,017,904 shares, or 7.5%, of Alnylam Pharmaceuticals Inc. common stock, with the event date of September 30, 2026 and the filing signed on November 16, 2026.